Leap Therapeutics Ownership
| LPTX Stock | USD 0.36 0.02 5.06% |
Shares in Circulation | First Issued 2013-03-31 | Previous Quarter 41.3 M | Current Value 41.3 M | Avarage Shares Outstanding 8.5 M | Quarterly Volatility 11.8 M |
Leap Stock Ownership Analysis
About 16.0% of the company outstanding shares are owned by corporate insiders. The company has price-to-book ratio of 0.7. Typically companies with comparable Price to Book (P/B) are able to outperform the market in the long run. Leap Therapeutics has Price/Earnings To Growth (PEG) ratio of 0.75. The entity recorded a loss per share of 1.67. The firm had not issued any dividends in recent years. Leap Therapeutics had 1:10 split on the 21st of June 2023. Leap Therapeutics, Inc., a biopharmaceutical company, acquires and develops therapies for the treatment of cancer. Leap Therapeutics, Inc. was incorporated in 2011 and is based in Cambridge, Massachusetts. Leap Therapeutics operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 36 people. To find out more about Leap Therapeutics contact the company at 617 714 0360 or learn more at https://www.leaptx.com.Besides selling stocks to institutional investors, Leap Therapeutics also allocates a substantial amount of its earnings to a pull of share-based compensation to be paid out to its employees, managers, executives, and members of the board of directors. Share-Based compensation (also sometimes called Stock-Based Compensation) is a way of paying different Leap Therapeutics' stakeholders with equity in the business. It is typically used as a motivation factor for employees to contribute beyond their regular compensation (salary and bonus). It is also used as a tool to align Leap Therapeutics' strategic interests with those of the company's shareholders. Shares issued to employees are usually subject to a vesting period before they are earned and sold.
Leap Therapeutics Quarterly Liabilities And Stockholders Equity |
|
About 16.0% of Leap Therapeutics are currently held by insiders. Unlike Leap Therapeutics' institutional investors, corporate insiders most likely have a limit on the maximum percentage of share ownership. This is done to align insiders' influence against Leap Therapeutics' private investors even though both sides will benefit from rising prices or experience loss when the share price declines. The good rule to have in mind is that the maximum share ownership percentage of the corporate insiders should not surpass 25%. View all of Leap Therapeutics' insider trades
Leap Stock Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Leap Therapeutics is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Leap Therapeutics backward and forwards among themselves. Leap Therapeutics' institutional investor refers to the entity that pools money to purchase Leap Therapeutics' securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Blackrock Inc | 2025-03-31 | 201.7 K | State Street Corp | 2025-03-31 | 125.6 K | Adar1 Capital Management Llc | 2025-03-31 | 111 K | Ubs Group Ag | 2025-03-31 | 108.4 K | Northern Trust Corp | 2025-03-31 | 61.6 K | Lpl Financial Corp | 2025-03-31 | 53.4 K | Hightower Advisors, Llc | 2025-03-31 | 50.5 K | Jane Street Group Llc | 2025-03-31 | 33 K | Integrity Alliance, Llc. | 2025-03-31 | 29.2 K | Samsara Biocapital, Llc | 2025-03-31 | 2.4 M | 683 Capital Management Llc | 2025-03-31 | 1.4 M |
Leap Therapeutics Insider Trading Activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Leap Therapeutics insiders, such as employees or executives, is commonly permitted as long as it does not rely on Leap Therapeutics' material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Leap Therapeutics insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Leap Therapeutics Outstanding Bonds
Leap Therapeutics issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Leap Therapeutics uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Leap bonds can be classified according to their maturity, which is the date when Leap Therapeutics has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| LEAR P 38 Corp BondUS521865AY17 | View | |
| US521865AZ81 Corp BondUS521865AZ81 | View | |
| US521865BB05 Corp BondUS521865BB05 | View | |
| LEA 26 15 JAN 32 Corp BondUS521865BC87 | View | |
| LEA 355 15 JAN 52 Corp BondUS521865BD60 | View | |
| US521865BA22 Corp BondUS521865BA22 | View | |
| MPLX LP 4125 Corp BondUS55336VAK61 | View | |
| MPLX LP 52 Corp BondUS55336VAL45 | View |
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Leap Stock Analysis
When running Leap Therapeutics' price analysis, check to measure Leap Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Leap Therapeutics is operating at the current time. Most of Leap Therapeutics' value examination focuses on studying past and present price action to predict the probability of Leap Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Leap Therapeutics' price. Additionally, you may evaluate how the addition of Leap Therapeutics to your portfolios can decrease your overall portfolio volatility.